Q1: 2026-05-07 Earnings Summary
EPS of $5.53 beats by $0.61
|
Revenue of
$1.31B
(64.63% Y/Y)
beats by $1.73M
argenx SE (ARGX) Q1 2026 Earnings Call May 7, 2026 8:30 AM EDT
Company Participants
Beth DelGiacco
Karen Massey - CEO & Executive Director
Karl Gubitz - Chief Financial Officer
Sandrine Piret-Gerard - Chief Commercialization Officer
Conference Call Participants
Yatin Suneja - Guggenheim Securities, LLC, Research Division
Tazeen Ahmad - BofA Securities, Research Division
Derek Archila - Wells Fargo Securities, LLC, Research Division
James Gordon - Barclays Bank PLC, Research Division
Alexander Thompson - Stifel, Nicolaus & Company, Incorporated, Research Division
Rajan Sharma - Goldman Sachs Group, Inc., Research Division
Ashleigh Acker - Piper Sandler & Co., Research Division
Alexander Nackenoff - Truist Securities, Inc., Research Division
Yaron Werber - TD Cowen, Research Division
Thomas Smith - Leerink Partners LLC, Research Division
Akash Tewari - Jefferies LLC, Research Division
Sean Laaman - Morgan Stanley, Research Division
Yixin Zhang
Jacob Mekhael - KBC Securities NV, Research Division
Victor Floch - BNP Paribas, Research Division
John Boyle - William Blair & Company L.L.C., Research Division
Samantha Semenkow - Citigroup Inc., Research Division
Presentation
Operator
Good morning. My name is David, and I'll be your conference operator today. I would like to welcome everyone to the call. [Operator Instructions] I'd like to introduce Beth DelGiacco, Vice President of Corporate Affairs. You may now begin your call.
Beth DelGiacco
Thank you. A press release was issued earlier today with our first quarter 2026 financial results and business update. This can be found on our website along with the presentation for today's webcast.
Before we begin on Slide 2, I'd like to remind you that forward-looking statements may be presented during this call. These may include statements about our future expectations, clinical development, regulatory time lines, the potential success of our product candidates, financial projections and upcoming milestones. Actual results may differ materially from those indicated by these statements. Argenx is not under any obligation to update statements regarding the future or to conform those statements in relation to
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。